HDAC6 inhibitors have been reported to reverse the malignant phenotype of glioma cells by forcing their differentiation, as measured by reduction of the proliferative marker Ki67 and enhancement of differentiation markers such as TUJ1 [1,3]. This evidence concerns the gene MKI67 and central nervous system cancer.